Sharmin Khan

Researcher

University of Arkansas for Medical Sciences

faculty

12 h-index 95 pubs 666 cited

Research Areas

Links

Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Sharmin Khan's research investigates mechanisms of bone destruction in the context of cancer metastasis and multiple myeloma. Her work has identified senescent osteocytes as key contributors to bone loss in breast cancer metastasis, as revealed by single-cell transcriptomic analysis. Khan has also elucidated signaling axes that promote chemoresistance and regulate osteocyte function in multiple myeloma, including pathways involving NOTCH3-CXCL12 and CCL3-HMGB1. Her recent publications explore therapeutic strategies, such as targeting the myeloma bone marrow niche with Notch inhibitors to decrease tumor growth and bone destruction while mitigating gut toxicity. Additionally, her research has examined the potential of sclerostin inhibition to heal lytic lesions and restore bone health in multiple myeloma. Khan's scholarship metrics include an h-index of 12, 95 total publications, and 666 total citations.

Metrics

h-index: 12
Publications: 95
Citations: 666

Selected Publications

Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025) DOI
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024) DOI
Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis (2024) DOI
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma (2024) DOI
Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity (2023) DOI
Abstract 5675: Pathological crosstalk between osteocytes and breast cancer cells in bone metastasis (2022) DOI